Please login to the form below

Not currently logged in
Email:
Password:

Novartis completes Alcon deal

Novartis has announced it has acquired 77 per cent majority ownership of Alcon, a Swiss medical company specialising in eye-care products

Novartis has announced it has completed a deal giving the company 77 per cent majority ownership of Alcon, a Swiss medical company specialising in eye-care products.

Novartis, also based in Switzerland, became the majority owner after finalising the acquisition of 52 per cent of Alcon shares from Nestlé for a total of $28.3bn. Novartis had previously acquired a 25 per cent stake in Alcon in July 2008.

"We are delighted to become majority owners of Alcon. Together, both companies can achieve their strategic priorities to deliver against patient needs through innovative and differentiated products" said Joe Jimenez, CEO of Novartis.

Alcon is the world's largest eye-care company, with 2009 sales of $6.5bn and a net income of $2.0bn.

As part of the deal, the US Federal Trade Commission (FTC) said Novartis must sell eye drug Miochol-E (acetylcholine chloride), an injectable eye care drug used in cataract surgery.

Plans for a complete takeover of Alcon were announced at the beginning of 2010 though the deal ran into problems when minority public shareholders voiced concerns that Novartis had offered two groups of Alcon shareholders two different prices for the same stock.

Novartis has said a direct merger of Alcon into Novartis is proposed under the Swiss Merger Act at a fixed exchange ratio of 2.8 Novartis shares for each remaining Alcon share in order to acquire the remaining 23 per cent of stock.

26th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....